Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Bioavailability of AZD5462 in Healthy Men
NCT06989983Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AZD5462 in heart failure (HF), sponsored by AstraZeneca. Primary endpoints: Amount of AZD5462 excreted, Fraction of AZD5462 excreted and 1 more. Started May 2025; status: completed.
02
Drugs
AZD5462
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06989983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06989983.